川崎病的辅助治疗
Adjunctive therapies in Kawasaki disease.
作者信息
Tremoulet Adriana H
机构信息
Kawasaki Disease Research Center, University of California San Diego, La Jolla, CA, USA.
出版信息
Int J Rheum Dis. 2018 Jan;21(1):76-79. doi: 10.1111/1756-185X.13208. Epub 2017 Oct 27.
Abstract
Despite the administration of intravenous immunoglobulin (IVIg) at a dose of 2 g/kg, approximately 3-5% of children with acute Kawasaki disease (KD) may develop coronary artery aneurysms. IVIg-resistance, defined as recrudescence of fever more than 36 h after IVIg completion, is a risk factor for coronary artery abnormalities. Thus, several adjunctive therapies are being evaluated for use in IVIg-resistant KD patients and in patients with coronary artery abnormalities. In this review the role of some of these adjunctive therapies in treatment of children with KD is discussed.
摘要
尽管静脉注射免疫球蛋白（IVIg）的剂量为2 g/kg，但约3-5%的急性川崎病（KD）患儿仍可能发生冠状动脉瘤。IVIg抵抗定义为IVIg输注结束后36小时以上仍有发热复发，是冠状动脉异常的一个危险因素。因此，正在评估几种辅助治疗方法用于IVIg抵抗的KD患者和冠状动脉异常患者。在这篇综述中，讨论了其中一些辅助治疗方法在KD患儿治疗中的作用。
相似文献
1
Adjunctive therapies in Kawasaki disease.川崎病的辅助治疗
Int J Rheum Dis. 2018 Jan;21(1):76-79. doi: 10.1111/1756-185X.13208. Epub 2017 Oct 27.
2
Role of intravenous immunoglobulin in the treatment of Kawasaki disease.静脉注射免疫球蛋白在川崎病治疗中的作用。
Int J Rheum Dis. 2018 Jan;21(1):64-69. doi: 10.1111/1756-185X.13220. Epub 2017 Dec 5.
3
Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.英夫利昔单抗治疗川崎病的疗效优于免疫球蛋白：荟萃分析。
Eur J Pharmacol. 2021 May 15;899:173985. doi: 10.1016/j.ejphar.2021.173985. Epub 2021 Feb 27.
4
Role of glucocorticoids in Kawasaki disease.糖皮质激素在川崎病中的作用。
Int J Rheum Dis. 2018 Jan;21(1):70-75. doi: 10.1111/1756-185X.13209. Epub 2017 Nov 3.
5
Risk Factors of Coronary Artery Aneurysms in Kawasaki Disease with a Low Risk of Intravenous Immunoglobulin Resistance: An Analysis of Post RAISE.川崎病伴低丙种球蛋白血症静脉用免疫球蛋白抵抗风险的冠状动脉瘤危险因素：POST-RAISE 分析。
J Pediatr. 2022 Jan;240:158-163.e4. doi: 10.1016/j.jpeds.2021.08.065. Epub 2021 Aug 27.
6
Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.土耳其儿童川崎病：单中心经验，重点关注静脉注射免疫球蛋白抵抗和巨大冠状动脉瘤
Turk J Pediatr. 2019;61(5):648-656. doi: 10.24953/turkjped.2019.05.002.
7
High-dose aspirin for Kawasaki disease: outdated myth or effective aid?大剂量阿司匹林治疗川崎病：过时的误区还是有效的辅助手段？
Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):209-212. Epub 2017 Jan 5.
8
The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.川崎病比较有效性（KIDCARE）试验：一种比较二线静脉注射免疫球蛋白与英夫利昔单抗治疗抵抗性川崎病的 III 期随机试验。
Contemp Clin Trials. 2019 Apr;79:98-103. doi: 10.1016/j.cct.2019.02.008. Epub 2019 Mar 3.
9
Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.川崎病患者早期静脉注射免疫球蛋白治疗。
J Pediatr. 2002 Apr;140(4):450-5. doi: 10.1067/mpd.2002.122469.
10
The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值联合作为川崎病患者静脉注射免疫球蛋白抵抗的新型预测指标：一项多中心研究
Heart Vessels. 2020 Oct;35(10):1463-1472. doi: 10.1007/s00380-020-01622-z. Epub 2020 May 24.
引用本文的文献
1
Multisystem inflammatory syndrome in children and Kawasaki disease.儿童多系统炎症综合征与川崎病
Front Immunol. 2025 Apr 15;16:1554787. doi: 10.3389/fimmu.2025.1554787. eCollection 2025.
2
Learning-Based Models for Predicting IVIG Resistance and Coronary Artery Lesions in Kawasaki Disease: A Review of Technical Aspects and Study Features.基于学习的川崎病静脉注射免疫球蛋白抵抗和冠状动脉病变预测模型：技术方面与研究特征综述
Paediatr Drugs. 2025 Apr 3. doi: 10.1007/s40272-025-00693-7.
3
Pharmacoeconomic Analysis and Considerations for the Management of Kawasaki Disease in the Arab Countries-A Multinational, Multi-Institutional Project of the Kawasaki Disease Arab Initiative (Kawarabi) (A Project Methodology Paper).阿拉伯国家川崎病管理的药物经济学分析与考量——川崎病阿拉伯倡议（Kawarabi）的一项多国多机构项目（项目方法文件）
Turk Arch Pediatr. 2025 Mar 3;60(2):172-181. doi: 10.5152/TurkArchPediatr.2025.24248.
4
The Central Role of Interleukin-1 Signalling in the Pathogenesis of Kawasaki Disease Vasculitis: Path to Translation.白细胞介素-1信号在川崎病血管炎发病机制中的核心作用：转化之路
Can J Cardiol. 2024 Dec;40(12):2305-2320. doi: 10.1016/j.cjca.2024.07.023. Epub 2024 Jul 30.
5
Association of Acute Anti-inflammatory Treatment With Medium-term Outcomes for Coronary Artery Aneurysms in Kawasaki Disease.川崎病冠状动脉瘤急性抗炎治疗与中期预后的关联
CJC Pediatr Congenit Heart Dis. 2022 Jun 17;1(4):174-183. doi: 10.1016/j.cjcpc.2022.05.007. eCollection 2022 Aug.
6
Anti-Inflammatory and Immunomodulatory Effect of High-Dose Immunoglobulins in Children: From Approved Indications to Off-Label Use.大剂量免疫球蛋白在儿童中的抗炎和免疫调节作用：从批准的适应证到超适应证使用。
Cells. 2023 Oct 7;12(19):2417. doi: 10.3390/cells12192417.
7
Concomitant Kawasaki Disease and Rotavirus Infection-More Than Just a Coincidence: A Case Report.川崎病与轮状病毒感染并存——绝非巧合：一例报告
Trop Med Infect Dis. 2023 Jul 29;8(8):388. doi: 10.3390/tropicalmed8080388.
8
An Update on Reports of Atypical Presentations of Kawasaki Disease and the Recognition of IVIG Non-Responder Children.川崎病非典型表现报告及静脉注射免疫球蛋白无反应儿童识别的最新进展
Diagnostics (Basel). 2023 Apr 17;13(8):1441. doi: 10.3390/diagnostics13081441.
9
Interleukin-33/ST2 Axis as Potential Biomarker and Therapeutic Target in Kawasaki Disease.白细胞介素-33/ST2轴作为川崎病潜在的生物标志物和治疗靶点
Inflammation. 2023 Feb;46(1):480-490. doi: 10.1007/s10753-022-01753-7. Epub 2022 Oct 8.
10
Serum alanine aminotransferase level and intravenous immunoglobulin resistance in patients with kawasaki disease.川崎病患者血清丙氨酸氨基转移酶水平与静脉注射免疫球蛋白抵抗。
Clin Rheumatol. 2022 Oct;41(10):3125-3133. doi: 10.1007/s10067-022-06278-w. Epub 2022 Jul 7.
本文引用的文献
1
High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease.6个月以下患有川崎病的婴儿发生冠状动脉瘤的风险较高。
J Pediatr. 2017 Jun;185:112-116.e1. doi: 10.1016/j.jpeds.2017.03.025. Epub 2017 Apr 10.
2
miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease.miR-483靶向结缔组织生长因子抑制内皮-间充质转化：对川崎病的治疗意义
Circ Res. 2017 Jan 20;120(2):354-365. doi: 10.1161/CIRCRESAHA.116.310233. Epub 2016 Dec 6.
3
Evaluating a novel treatment for coronary artery inflammation in acute Kawasaki disease: A Phase I/IIa trial of atorvastatin.评估急性川崎病冠状动脉炎症的新型治疗方法：阿托伐他汀的I/IIa期试验。
Expert Opin Orphan Drugs. 2015;3(9):967-970. doi: 10.1517/21678707.2015.1066246. Epub 2015 Jul 13.
4
Non-Responders to Intravenous Immunoglobulin and Coronary Artery Dilatation in Kawasaki Disease: Predictive Parameters in Korean Children.川崎病中静脉注射免疫球蛋白无反应者与冠状动脉扩张：韩国儿童的预测参数
Korean Circ J. 2016 Jul;46(4):542-9. doi: 10.4070/kcj.2016.46.4.542. Epub 2016 Jul 21.
5
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).一项评估免疫球蛋白联合环孢素A治疗重症川崎病疗效和安全性的Ⅲ期多中心、随机、开放标签、盲终点试验的研究方案（KAICA试验）
BMJ Open. 2015 Dec 1;5(12):e009562. doi: 10.1136/bmjopen-2015-009562.
6
Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease.全基因组表达谱分析确定了急性川崎病的新治疗靶点。
Genome Med. 2014 Nov 20;6(11):541. doi: 10.1186/s13073-014-0102-6. eCollection 2014.
7
Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.江见评分在预测不同种族川崎病患者静脉注射免疫球蛋白抵抗中的作用
Am J Ther. 2016 Nov/Dec;23(6):e1293-e1299. doi: 10.1097/MJT.0000000000000045.
8
A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease.静脉注射免疫球蛋白抵抗型川崎病再治疗的荟萃分析。
Cardiol Young. 2015 Aug;25(6):1182-90. doi: 10.1017/S1047951114002601. Epub 2015 Jan 19.
9
[Cyclosporin A treatment for refractory Kawasaki disease].环孢素A治疗难治性川崎病
Nihon Rinsho. 2014 Sep;72(9):1636-40.
10
Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms.阿托伐他汀在患有冠状动脉瘤的川崎病患者中的安全性。
Pediatr Cardiol. 2014 Jan;35(1):89-92. doi: 10.1007/s00246-013-0746-9. Epub 2013 Jul 18.
Zotero 插件